4 completed, 3 recruiting, 2 active not recruiting, 2 not yet recruiting. 12 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 4, Recruiting 3, Active not recruiting 2, Not yet recruiting 2, Terminated 1 |
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
Follow Methamphetamine Use Disorder: new trials by email Literature Review of Methamphetamine Use Disorder trials Research Report on Methamphetamine Use Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Psilocybin for Methamphetamine Use Disorder Psilocybin (single oral capsule administered at one of two dose levels, Dose A or Dose B; specific doses withheld during conduct)., Manualized cognitive behavioral therapy platform (2 preparation + 2 integration sessions). - Methamphetamine Use Disorder | Phase 2 | Not yet recruiting | Peter Hendricks | 42 | 2027-02-01 | 2026-09-21 |
| Psilocybin Therapy for Methamphetamine Use Disorder and HIV Psilocybin 5 mg, Psilocybin 25 mg, Motivational Support - Methamphetamine Use Disorder, Human Immunodeficiency Virus (HIV) | Phase 2 | Recruiting | Nicky Mehtani, MD, MPH | 30 | 2026-12-01 | 2026-11-09 |
| Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder Tirzepatide, Placebo (saline) - Methamphetamine Use Disorder | Phase 2 | Recruiting | University of Texas Southwestern Medical Center | 228 | 2026-10-23 | 2026-10-26 |
| Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study 12 weeks of weekly subcutaneous semaglutide injection - Methamphetamine Use Disorder | Phase 2 | Not yet recruiting | Kirby Institute | 40 | 2026-09-01 | 2026-06-26 |
| An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder Tirzepatide - Obesity, Methamphetamine Use Disorder | Phase 2 | Active not recruiting | University of Texas Southwestern Medical Center | 45 | 2026-08-19 | 2026-10-29 |
| Feasibility of Long-term, High-dose Stimulant for Methamphetamine Use Disorder LDX-01 plus TAU, Placebo plus TAU - Methamphetamine Abuse, Methamphetamine-dependence | Phase 2 | Recruiting | Centre hospitalier de l'Université de Montréal (CHUM) | 80 | 2025-07-18 | 2026-02-23 |
| Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV Ketamine, Psychotherapy - Methamphetamine Use Disorder | Phase 2 | Completed | Nicky Mehtani, MD, MPH | 17 | 2025-03-04 | 2026-08-12 |
| Tirzepatide for Obesity and Meth Use Disorder Tirzepatide - Obesity, Methamphetamine Use Disorder | Phase 2 | Completed | University of Texas Southwestern Medical Center | 35 | 2025-02-03 | 2026-09-28 |
| Deep Brain Stimulation (DBS) for Methamphetamine Use Disorder Experimental 1 - DBS of bilateral NAc - 6 months of active stimulation -- > 6 months of sham stimulation, Experimental 2 - DBS of bilateral NAc - 6 months of sham stimulation -- > 6 months of active stimulation - Methamphetamine Use Disorder | Phase 1 / Phase 2 | Active not recruiting | University of Colorado, Denver | 2 | 2024-01-15 | 2025-04-30 |
| The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder suvorexant (SUVO), Placebo - Methamphetamine Use Disorder | Phase 2 | Terminated | The University of Texas Health Science Center, Houston | 7 | 2023-03-09 | 2025-04-29 |
| Intermittent Oral Naltrexone Enhanced With an Ecological Momentary Intervention for Methamphetamine-using MSM Naltrexone Hydrochloride, Placebo, Ecological Momentary Intervention - Methamphetamine Use Disorder | Phase 2 | Completed | Glenn-Milo Santos | 60 | 2021-12-14 | 2025-10-27 |
| Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder naltrexone plus bupropion - Methamphetamine Use Disorder | Phase 1 / Phase 2 | Completed | Walter Ling | 49 | 2013-11-01 | 2020-03-23 |
Substance-Related Disorders (4) · Behavior, Addictive (2) · Obesity (2) · Overweight (2) · Acquired Immunodeficiency Syndrome (1) · Amphetamine-Related Disorders (1) · Chemsex (1) · Sexual Behavior (1) · Sleep Initiation and Maintenance Disorders (1)
Mental Disorders (6) · Chemically-Induced Disorders (5) · Behavior (3) · Body Weight (2) · Compulsive Behavior (2) · Impulsive Behavior (2) · Nutrition Disorders (2) · Nutritional and Metabolic Diseases (2) · Overnutrition (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Blood-Borne Infections (1) · Communicable Diseases (1) · Dyssomnias (1) · Genital Diseases (1)
Tirzepatide (3) · Naltrexone (2) · Psilocybin (2) · Bupropion (1) · Floors and Floorcoverings (1) · Ketamine (1) · Motivational Interviewing (1) · Psychotherapy (1) · Sodium Chloride (1) · Therapeutics (1) · suvorexant (1)
University of Texas Southwestern Medical Center (3) · Nicky Mehtani, MD, MPH (2) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · Glenn-Milo Santos (1) · Kirby Institute (1) · Peter Hendricks (1) · The University of Texas Health Science Center, Houston (1) · University of Colorado, Denver (1) · Walter Ling (1)
United States (10) · Australia (1) · Canada (1)
Manish Jha, M.B.B.S. (2) · Didier Jutras-Aswad, MD (1) · Glenn-Milo Santos, PhD, MPH (1) · Heather Webber, PhD (1) · Larissa Mooney, M.D. (1) · Manish Jha, MBBS (1) · Nicky J. Mehtani, MD, MPH (1) · Nicky Mehtani, MD MPH (1) · Peter S Hendricks, PhD (1) · Walter Ling, M.D. (1)
PMID 30724759, PMID 39731508, PMID 40850924
1DP2DA066200 (1), 1UG3DA067126 (1), 2025 (1), 2KL2TR001870 (1), R01DA053171 (1), U10DA013045 (1), UG3DA054746 (1)